Newsroom
Find everything you need for reporting on Teva: press releases, media kits, leadership information, and direct contacts for our communications team.
Press releases
Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030
Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial Gross Margin Expansion
Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.
Media assets
Our Stories
Teva’s High-Velocity Biopharma Model
Meet Our People: Jessica Kurth, Drug Product Tech Transfer Scientist
“When We Say We Want to Be Innovative, We Mean It”
Meet our People: Bin Ni Bioanalysis Scientist, Specialty Bioanalytics
Meet Our People: Assaf Marcus Director of Clinical Biomarkers, Translational Medicine
The Future of R&D Is Powered by Partnerships
Q3 business highlights at a glance
Understanding Schizophrenia: The Human Impact, the Clinical Challenges and the Importance of Stability in Care
Teva in Q2 2026: Our transformation at a glance
Teva in Q1 2026: Our transformation at a glance
Meet Our Leadership Team
Richard Francis
President and Chief Executive Officer, Member of the Board of Directors
Richard Daniell
Executive Vice President, European Commercial
Christine Fox
Executive Vice President, US Commercial, Head of Innovative Franchise
Dr. Eric A. Hughes
Executive Vice President, Global R&D and Chief Medical Officer
Placid Jover
Executive Vice President, Chief Human Resources Officer
Eli Kalif
Executive Vice President, Chief Financial Officer (CFO)
Evan Lippman
Executive Vice President, Business Development
Mark Sabag
Executive Vice President, International Markets Commercial
Matthew Shields
Executive Vice President, Teva Global Operations
Nir Baron
Senior Vice President, Chief Internal Auditor
Kathleen Veit
Senior Vice President, Global Compliance & Ethics Officer